Curis heads into its May 7 earnings call carrying a notable tension: a cluster of insider purchases in mid-March, a new institutional stakeholder that just filed a 13G, and a stock that has punished investors after each of its last two results.
The clearest reason for attention this week is the ownership picture. In mid-March, Curis's CFO James Dentzer, Chief Medical Officer Ahmed Hamdy, and an independent director all bought stock in the open market — a cluster of C-suite purchases worth a combined $270,000-plus. That kind of coordinated buying in a sub-dollar biotech is worth flagging on its own. Then, on April 24, Nantahala Capital Management filed a Schedule 13G disclosing a fresh 2,000,000-share position — roughly 5% of the company. Stonepine Capital already holds 9.3%. These two names together account for more than 14% of outstanding shares, a concentration that gives the ownership table real weight heading into a catalyst.
Short positioning tells a more complicated story this week. Estimated short interest tripled over the past week — from around 0.17% of the free float in mid-April to roughly 0.60% as of April 28. That move is large in percentage terms but small in absolute terms; Curis is a micro-cap trading at $0.56, and the share count being shorted remains tiny. Cost to borrow has eased considerably — from above 14% in late March to 7.7% now — which points to a loosening in the lending market rather than any squeeze dynamic. Availability has widened in tandem, consistent with a borrow market that is comfortably supplied despite the recent uptick in short positioning. The ORTEX short score of 32.6, ranked in the 69th percentile by days-to-cover, reflects modest rather than extreme short-side pressure.
The Street angle on Curis is narrow. Coverage is effectively limited to HC Wainwright, which reiterated its Buy in late March. The stated price target of $17 sits so far above the current $0.56 price that it offers little useful valuation signal — it is best read as a placeholder from an analyst maintaining coverage rather than an actionable anchor. The analyst consensus is formally "Buy," but with three analysts and a stock near its lows, the label carries limited weight. Factor scores are mixed: a DTC rank of 79 and a sector score of 50 suggest the stock is neither a pure squeeze candidate nor a fundamental leader within biotech. The EPS surprise score of 3 — very low — reflects a history of missing estimates.
That last point sharpens the May 7 setup considerably. The two most recent earnings events both produced sharp declines: the March 26 print triggered a one-day fall of 20.7% and a five-day drop of 21.5%. The March 19 event fell 5.4% on the day and 28.8% over five days. The pattern is consistent — Curis has not rewarded holders in the days following results. With the stock already down 8.6% on the week and roughly flat over the past month, the price has not recovered from those moves.
The narrative heading into May 7 is therefore less about short pressure — which is modest — and more about whether the insider and institutional buying signals a genuine inflection in the pipeline story, or simply reflects conviction in a deeply discounted biotech. The Nantahala 13G filing and the C-suite cluster are the data points most worth tracking at the next print.
See the live data behind this article on ORTEX.
Open CRIS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
